Abaloparatide

Abaloparatide Brand Name

TYMLOS

What is Abaloparatide

Abaloparatide is an analog of human parathyroid hormone related peptide, PTHrP (1-34).

It is used for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.

Similar to teriparatide, the abaloparatide label contains a boxed warning regarding the risk of osteosarcoma and the drug is not recommended for use in patients at risk for osteosarcoma.

In addition, cumulative use of abaloparatide and parathyroid hormone analogs (e.g., teriparatide) for more than 2 years during a patient’s lifetime is not recommended.

Abaloparatide was approved by the FDA in April 2017.

Indications

  • osteoporosis

For the treatment of postmenopausal women with osteoporosis at high risk for fracture

Side Effects

  1. abdominal pain
  2. antibody formation
  3. dizziness
  4. fatigue
  5. headache
  6. hypercalcemia
  7. hypercalciuria
  8. hyperuricemia
  9. injection site reaction
  10. nausea
  11. nephrolithiasis
  12. new primary malignancy
  13. orthostatic hypotension
  14. osteogenic sarcoma
  15. palpitations
  16. sinus tachycardia
  17. vertigo

Monitoring Parameters

  • serum calcium
  • serum uric acid

Contraindications

  • breast-feeding
  • children
  • hypercalcemia
  • hypercalciuria
  • hyperparathyroidism
  • infants
  • nephrolithiasis
  • new primary malignancy
  • orthostatic hypotension
  • osteogenic sarcoma
  • pregnancy
  • radiation therapy
  • renal failure
  • renal impairment

Interactions

There are no drug interactions associated with Abaloparatide products.

15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856
Scroll to Top